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1. Introduction 
Coronary (CAD) and peripheral (PAD) artery disease are major causes of morbidity and 
mortality, requiring bypass surgery or angioplasty in approximately one million 
patients/year in the world (MERIT-HF Study Group, 1999). While collateral vessel 
formation as an alternative pathway for blood supply occurs in some of these patients, 
many do not form vascular networks adequate to compensate for the loss of the original 
blood supply (Hirsch et al., 2006). These patients might therefore benefit from stem cell 
transplantation therapies that would accelerate natural processes of postnatal collateral 
vessel formation, an approach referred to as therapeutic angiogenesis. On the other hand, 
recent seminal reports have indicated that the adult heart is self-healing and self-renewing. 
Specifically, these studies have demonstrated that there is a pool of resident cardiac stem 
cells (CSCs) that are clonogenic and multipotent and are capable of differentiating into new 
blood vessels or into new myocytes, and of cardiac progenitor cells (CPCs) (Marban, 2007). 
This suggests the possibility of using a therapeutic angiogenesis approach to complement 
other treatments (e.g., stem cell therapy) that facilitate myocardial repair. Such combined 
modalities may facilitate myocardial regeneration by inducing endogenous cardiac cells to 
migrate, differentiate, and proliferate in situ, replacing lost endothelial cells and 
cardiomyocytes (Urbaneket al., 2005). However, despite recent progress in applying the 
approaches of regenerative medicine to the treatment of such diseases, valid strategies 
aimed at repairing the infarcted heart and, in general, at treating end-organ ischemia 
continue to be elusive. Major obstacles are the difficulty in isolating and delivering stem 
cells that are specifically effective in myocardial repair, and in stimulating recruitment of 
endogenous stem cells to the ischemic tissue. To address these issues, there has been 
increasing focus on novel biotechnologies or pharmacological strategies to enhance the 
implantation of exogenous stem cells or to boost endogenous regeneration of myocardial 
tissue. By employing three fundamental “tools”, namely stem cells, biomaterials and growth 
factors (GFs) (Lavik & Langer, 2004; Mikos et al., 2006), such tissue engineering strategies 
may enhance the efficacy of stem cell therapy in several ways: by mobilizing endogenous 
stem/progenitor cells in vivo; by promoting cell proliferation and differentiation; and by 
augmenting cell engraftment and survival in the injured myocardium. In general, because of 
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the short half-lives of GFs in the body and the necessity to deliver them to specific target 
sites, GF injections themselves do not always produce the anticipated therapeutic effect. At 
present, GF delivery in regenerative medicine basically relies upon two strategies: 1) 
delivery of the GF genes; 2) direct delivery of GFs by incorporating them into a vehicle. In 
the gene delivery approach, delivery of the GF gene may result in higher and more constant 
levels of protein produced, since the gene - rather than a degradable protein -  is being 
delivered (Haastert & Grothe, 2007). Two major problems are associated however with this 
approach: 1) the complexity of cloning and integrating the gene into the target cells; 2) safety 
and efficiency of transduction. At present, there are insufficient well-controlled long-term 
studies in the preclinical area to make any conclusive statements about the clinical 
suitability/efficacy of gene delivery in humans. If resolved, cell-mediated synthesis of GFs 
should be associated with more efficient targeting of receptors and, consequently, a more 
robust and predictable approach in ischemic tissue regeneration. 
2. Stem cell basics and selection 
Stem cells are a population of immature tissue precursor cells capable of self-renewal as well 
as of differentiation into a spectrum of different cell types in appropriate conditions. In 
general, they share the following characteristics: (1) a high capacity for self-renewal; (2) the 
potential for differentiation in multiple cell types; (3) the ability to be cultured ex vivo and 
used for tissue engineering; and (4) plasticity (transdifferentiation ability) (Vats et al., 2005). 
On the basis of their differentiating potential, stem cells can currently be classified into four 
categories: (1) totipotent, (2) pluripotent, (3) multipotent, and (4) oligopotent or monopotent. 
Totipotent stem cells have the potential to differentiate into cells of all three main germinal 
layers (the ectodermal, endodermal, and mesodermal) and embryo-derived tissues. 
Pluripotent stem cells have the ability to differentiate only into tissues derived from the 
ectoderm, endoderm and mesoderm. Multipotent stem cells can differentiate into tissue-
specific progenitor cells within a given organ. For example, multipotent blood stem cell or 
hematopoietic stem cells can develop into red blood cells, white blood cells, or platelets. 
Oligopotent or monopotent stem cells can only give rise to one or few types of specialized 
cells. On the basis of their origin and biological properties, stem cells can also be classified as 
either (1) embryonic stem cells or (2) adult stem cells. Embryonic stem cells are derived from 
the inner layer mass of the blastocyst and can be harvested from three sources: aborted 
fetuses (cadaveric stem cells), embryos left over from in vitro fertilization (discarded 
embryos), and embryos created in the laboratory solely for the purpose of producing stem 
cells (research embryos). In vitro differentiation of human embryonic stem cells into 
cardiomyocytes has been demonstrated by Kehat et al. (Kehat et al., 2001). However, ethical 
issues have been raised against harvesting human embryonic stem cells, especially if this 
process requires destruction of an embryo. Other potential obstacles to using embryonic 
stem cells are that recipients often need to receive immunosuppressants, because embryonic 
stem cells are potentially allogenic and strongly immunogenic. Uncontrolled differentiation 
of embryonic stem cells may cause other problems, such as the development of cardiac or 
vascular neoplasm. Transplanted embryonic stem cells may form teratomas if some 
undifferentiated totipotent cells are still present.  The formation of teratomas -i.e., tumors 
containing a mix of differentiated human cell types, including cells characteristic of the 
ectoderm, mesoderm, and endoderm-in severe combined immunodeficiency (SCID) mice 
after injection with human embryonic stem cells has been observed (Thomson et al., 1998). 
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Adult stem cells are the undifferentiated cells that exist in a differentiated tissue or organ 
and that are capable of specializing into cells of the tissue or organ from which they 
originated. Their capacity for self-renewal allows tissues and organs to maintain functional 
stability. Sources of adult stem cells include not only regenerating tissues, such as the heart, 
adipose tissue, bone marrow, blood, liver and  epidermis, but also non-divisive tissues, such 
as the brain. Compared with embryonic stem cells, autologous adult stem cells are not faced 
with any major ethical or immunological controversies surrounding their use in the same 
individual from whom they were obtained. However, their ability to proliferate and 
differentiate is less powerful than that of embryonic stem cells; they are often difficult to 
identify, isolate, and purify; and they are not numerous enough for use in transplantation 
without being expanded in vitro substantially. For example, there is only one hematopoietic 
cell for every 1000-5000 bone marrow stromal cells (BMSCs). Adult stem cells do not 
replicate indefinitely in culture (Jiang et al., 2002), and they are referred to as multipotent or 
oligopotent stem cells. The partially differentiated cells are precursor or progenitor cells, 
which are characterized by the ability to proliferate. For instance, circulating endothelial 
progenitor cells (EPCs) can promptly differentiate into mature endothelial cells that replace 
dead or dying cells when the endothelium of arteries is injured by atherosclerosis (Urbich & 
Dimmeler, 2004).  
Selection of a suitable type of stem cells is a key issue for the success of stem cell therapy. 
Stem/progenitor cells used for transplantation should have the following characteristics: (1) 
high rates of survival and proliferation; (2) high capability of differentiation; and (3) the 
potential for engraftment and integration with native or host cardiac cells. Currently, both 
embryonic and adult stem cells are used in experimental cardiac cell transplantation studies, 
while only adult stem cells (e.g., bone marrow-derived mesenchymal cells, skeletal 
myoblasts, endothelial progenitor cells) are used in clinical trials. Each stem cell type has 
unique biological properties that offer both advantages and limitations to their use. 
Therefore, selection of the most suitable stem cells for use in ischemic patients is still a major 
focus of current research. The skeletal myoblasts or satellite cells are precursor cells of 
human skeletal muscle that originate from muscle stem cells (Angelis et al., 1999). They 
normally lie in a quiescent state under the basal membrane of muscular fibers, and have the 
potential for reentry into the cell cycle in response to injury, where they can divide and 
differentiate into functional muscle cells. Skeletal myoblasts can be obtained from individual 
patients themselves. Other theoretical advantages of using autologous skeletal myoblast are 
their rapid expansion in culture and their lower likelihood of tumor formation after 
transplantation. In addition, these cells have a chance of engrafting with native 
cardiomyocytes and surviving in infarcted regions of the heart since they are relatively 
resistant to ischemia. Animal studies have demonstrated that skeletal myoblasts can 
successfully accommodate themselves in the infarcted region of the heart, forming striated 
muscle fibers with intercalated discs in the host myocardium under the influence of factors 
in the cardiac environment (Murry et al., 1996). Improvement in systolic function has been 
noted after skeletal myoblast transplantation in ischemic and non-ischemic heart failure 
models (Atkins et al., 1999; Hagegeet al., 2001; Siminiak & Kurpisz, 2003). Controversy still 
exists regarding the capability of stem cells to engraft and connect with native 
cardiomyocytes, despite promising results from preclinical studies (Suzuki et al., 2001; 
Menasche et al., 2003; Pagani et al., 2003; Smits et al., 2003). Bone marrow-derived stem cells 
are currently the most commonly used cells in cell transplantation therapy. The ideal stem 
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cells from bone marrow for cardiac regeneration remain to be identified and many details 
remain to be elucidated. Yet, the clinical results from recent trials show the capability of 
these cells to ameliorate systo-diastolic heart function and decrease the size of the infarct 
region after intracoronary injection (Assmus et al., 2002; Strauer et al., 2002; Britten et al., 
2003). Other studies (Perin et al., 2002; Perin et al., 2003) have demonstrated the safety and 
efficacy of transendocardial injection of autologous bone marrow mononuclear cells in 
patients with end-stage ischemic heart disease. Fetal cardiomyocytes still can enter the cell 
cycle and be expanded in culture. Successful cell transplantation using fetal cardiomyocytes 
was initially demonstrated in mice (Soonpaa et al., 1994; Li et al., 1995; Li et al., 1996), with 
findings in improvement of heart function and formation of new blood vessels in and 
around the cell graft area (Watanabe et al., 1998). These experiments show that fetal 
cardiomyocyte transplantation is feasible and potentially clinically relevant. Besides the 
ethical questions concerning the use of human fetal tissue, however, one limitation of using 
fetal cardiomyocytes is that lifelong immunosuppressive therapy may be necessary to 
prevent rejection. The optimal regimen and dose of immunosuppressive agents for cell 
transplantation would be here still unknown. A large number of studies have examined the 
differentiation of embryonic stem cells into cardiomyocytes, aiming at clarifying the 
mechanism of differentiation, identifying cell markers, and developing techniques for 
purifying embryonic stem cell-derived cardiomyocytes. The pluripotency of embryonic stem 
cells gives rise to their differentiation into more than 200 hundred kinds of cell lines. 
Protocols for the in vitro differentiation of embryonic stem cells into cardiomyocytes 
representing all specialized cell types of the heart, such as atrial-like, ventricular-like, sinus 
nodal-like, and Purkinje-like cells, have been established. Only 5-10% of these cells have 
been identified as cardiomyocytes. It may be ideal to separate cardiomyocytes from the 
undifferentiated ES cells before transplantation because of their potential to generate tumor-
like tissue if implanted (Odorico et al., 2001). However, how to direct the differentiation of 
embryonic stem cells only into functional cardiomyocytes in vivo is still unclear. As stated 
above, another technical limitation is here the need for immunosuppressant therapy after 
transplantation. Endothelial progenitor cells can be identified in adult peripheral blood, 
bone marrow, and human umbilical cord blood.  
Current experiments suggest that EPCs play an important role in vasculogenesis by 
differentiating into vascular endothelial cells, inhibiting ventricular remodeling through 
improvement in myocardial blood supply (Kamihata et al., 2001). Adipose tissue-derived 
stem cells may overcome major limitations in the use of adult stem cells harvested from 
essential organs such as muscle, skin, brain. liver and bone marrow. It has been shown that 
these cells can be induced to differentiate into multiple cell lineages, including adipose, 
cartilage and bone, muscle cells, neurons and endothelial cells (Zuk et al., 2001; Madonna et 
al., 2009). Injection of adipose tissue-derived stromal cells (ADSCs) has been recently shown 
to improve neovascularisation in the ischemic hind limb and the infarcted heart (see 
Madonna et al., 2009 for a general review of preclinical studies in the heart and hind limb 
ischemia models). Furthermore, recent studies (Puissant et al., 2005) have reported on the in 
vivo and in vitro immunosuppressive properties of ADSCs and their capability of escaping 
the immune surveillance. Therefore, major advantages of the adipose tissue as an alternative 
source of regenerative cells, include: 1. yield: a therapeutic dose of regenerative cells can be 
isolated in approximately one hour without cell culture; 2. safety: patients receive their own 
cells (autologous-use), with no risk of immune rejection or transmission; 3. versatility: stem 
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cells from the adipose tissue benefit from multiple mechanisms of action. Recently it has 
been documented that the adult heart contains a pool of small cells expressing stem cell 
markers [c-kit, multi drug resistance 1 (MDR-1), and stem cell antigen 1 (Sca-1)]. Such cells 
also harbor telomerase activity, which is only present in replicating cells. These cardiac 
stem-progenitor cells (CSCs) not only can replenish the cardiomyocyte population, but are 
also able to regenerate coronary vessels (Beltrami et al., 2001). The actual number of CSCs 
remains controversial. Quantitative data in mouse, rat, dog, and human hearts have 
demonstrated that there is 1 CSC per approximately 30,000 to 40,000 myocardial cells: 
approximately 65% of all CSCs possess the 3 above-referred antigens (c-kit, MDR-1, and Sca-
1–like); approximately 20% possess 2, and approximately 15% possess only 1. 
Approximately 5% each of all CSCs exclusively express c-kit, MDR-1, or Sca-1. Furthermore, 
more premature resident CSCs, such as  cardiospheres and isl1+ cardioblasts, have been 
recently identified (Messina et al., 2004). This variability in the number and type of CSCs 
reflects cells with distinct functional capacity and different stage of differentiation. In vivo 
experiments have shown that injected cardiospheres can produce functional improvement 
of the heart, with 37% improvement in fractional shortening in the injected group (Messina 
et al., 2004; Smith et al., 2007; Chimenti et al., 2010). Main advantages of CSCs are the 
following: 1. CSCs are autologous, and thus unlikely to trigger infectious or immunological 
complications; 2. CSCs are more cardiogenic than other adult stem cells; 3. CSCs trigger 
robust angiogenic responses after myocardial transplantation. 
3. Growth factor selection and vehicle-based delivery approach  
Vehicle-based delivery systems for growth factors, derived from diverse biomaterials, are 
used to increase their retention at treatment sites for a sufficient period of time to allow 
tissue regenerating cells to migrate into the area of injury, to proliferate and to differentiate, 
as well as to reduce the loss of bioactivity. They are also used to control toxicity induced by 
high concentrations of growth factors (Vasita & Katti, 2006; Chou & Leong, 2007). A major 
challenge inherent in these strategies is to identify growth factors and signaling pathways 
that selectively promote proliferation, migration, engraftment, and differentiation of 
resident CSCs or exogenous multipotent stem cells. This challenge relates also to the 
understanding of cellular uptake mechanisms, cell response to the mechanochemical 
microenvironment, the potential therapeutic utility of delivered biomolecules, and the exact 
requirements for multiple signals to drive the ischemic cardiovascular tissue regeneration 
process to completion. Current knowledge suggests that ‘‘cocktails’’ of biomolecules, or 
even cocktails of different types of stem cells, should be delivered locally, with specific and 
distinct pharmacokinetics/pharmacodynamics (e.g., the capacity of each single component 
of the cocktail to act distinctly in differentiating or in homing different endogenous stem 
cell/progenitor population), in order to mimic, as far as possible, the different requirements 
of the ischemic tissue during the various regeneration phases. Engineering natural and/or 
synthetic scaffolds to release several growth factors (or growth factor-encoding genes) in a 
sequential manner might affect more than one phase of the ischemic tissue healing process, 
for example, neovascularization and myogenesis, ultimately leading to cardiovascular tissue 
regeneration rather than repair. The growth factors that have been most intensively 
investigated in the regeneration of ischemic cardiovascular tissues include vascular 
endothelial growth factor (VEGF), transforming growth factor (TGF)-β, platelet-derived 
growth factors (PDGF, including PDGF-BB and PDGF-AA), insulin-like growth factor (IGF)-
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1, basic fibroblast growth factor (b-FGF) (Beohar et al., 2010). Overall, results indicate that 
these growth factors elicit significant proliferative and angiogenic effects. It is now well 
established that the utilization of multiple growth factors, rather than one, capable to act in a 
concentration- and time-dependent manner, is essential in the processes involved in the 
regeneration of ischemic cardiovascular tissues (Chen et al., 2010). An example is given by 
the need of having VEGF and PDGF together in order to promote angiogenesis. Indeed, 
VEGF is an initiator of angiogenesis, while PDGF promotes blood vessel maturation. As an 
example for this, a polymer scaffold constructed from Poly (Lactide-co Glycolide) (PLG), 
capable of delivering VEGF and PDGF together, with better results in terms of formation of 
mature vessels compared with the delivery of VEGF or PDGF singularly, has been produced 
(Richardson et al., 2001). In the selection of growth factors potentially capable to boost the 
regeneration of ischemic cardiovascular tissue, we and others have investigated on 
hepatocyte growth factor (HGF) and its receptor receptor mesenchymal-epithelial transition 
factor (Met). Ligand-receptor systems such HGF and its receptor, the tyrosine kinase Met, 
are potential candidates for therapeutic angiogenesis and for boosting migration, 
engraftment and commitment of CSCs because they promote the translocation of CSCs into 
the injured area, activate their growth and differentiation, and stimulate endothelial cell 
migration (Rappolee et al., 1996; Forte et al., 2006; Madonna et al., 2010). The strategy of 
combining stem cells, either native or gene-engineered to overexpress growth factors, with 
biopolymers that are functionalized with growth factors such as HGF, would facilitate 
myocardial regeneration: a) by supplying exogenous stem cells or GFs that stimulate 
resident CSC migration, engraftment and commitment to cardiomyocytes, and that induce 
and modulate arterial responses to ischemia; b) by supporting the maintenance of GFs and 
transplanted stem cells in the damaged tissues through the use of biocompatible and 
biodegradable polymers for a period of time sufficient to allow histological and anatomical 
restoration of the damaged tissue. These polymers can provide vehicles to deliver bioactive 
factors and stem cells into the infarcted heart or ischemic cardiovascular tissues. Finally, this 
approach would promote the ability of resident CSCs or of exogenous multipotent stem 
cells, such as adipose tissue-derived mesenchymal stem cells (AT-MSCs), to induce the 
healing of damaged tissue, by recruiting and directing these cells into the damaged area, by 
improving angiogenesis and, finally, by promoting the reperfusion of ischemic tissues.  
4. Growth factor-delivery systems and devices in the treatment of tissue 
ischemia 
Many limitations of stem cell therapies could be resolved by stimulating specific cellular 
functions for cell populations that normally are quiescent in the adult heart or that are not 
capable of replacing the dying cells. Compounds (cytokines and growth factors) that are 
simply injected into the lesions quickly disappear from the site of injection because they are 
removed by the blood flow and degraded by specific enzymes located in the extracellular 
microenvironment. To overcome this drawback, a possible strategy is to install a polymer 
functionalized with growth factors and stem cells into the damaged heart to stimulate the 
natural process of cardiac repair. Polymers tested in the past for their ability to support 
transplanted cells, without any conjugation with functional molecules, have been marginally 
effective. More novel polymers are conjugated with functional molecules (growth factors, 
chemotactic factors, cytokines), and are capable of stimulating specific normally quiescent 
cellular functions (Tatard et al., 2005). They are known as “smart” polymers because they 
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“persuade” and guide the regenerative process, and are “biomimetics” because they use 
strategies occurring during the physiological regenerative process. Unlike the previous ones, 
novel polymers are “smart”, in that they can acquire several biological functions depending 
on the bioactive factor or stem cell type to which they are conjugated. These polymers can 
prolong and amplify specific stem cell functions. They can stimulate the recruitment of 
circulating and resident stem cells and subsequently promote their adhesion to the damaged 
area, and can enhance survival, proliferation, and differentiation of stem cells into cardiac 
and vascular cells (Madonna & De Caterina, 2009). Several of these features are critical to 
tissue regeneration, including restoration of the delivery of factors, nutrients, oxygen, and 
blood to necrotic tissues. To accomplish this, polymers must be functionalized by 
conjugation with bioactive factors. To date, delivery systems of growth factors are basically 
classified as: 1) reservoir systems; 2) environmentally responsive systems. Reservoir systems 
are one of the oldest methods used successfully to deliver drugs. The primary drug release 
mechanism from reservoir systems is diffusion-controlled release, characterized by an initial 
‘‘burst release’’ phase followed by a phase of slower drug release from the carrier (Langer, 
1983). Examples are hydrophilic matrices, that degrade when water enters and in this way 
release the drug (Franssen et al., 1999). Several reservoir systems have been developed to 
more closely control the release kinetics and avoid ‘‘burst type’’ release of the encapsulated 
factor(s). For example, the in vitro release of TGF-β from novel, injectable hydrogels based 
on the polymer oligo(poly(ethylene glycol) fumarate) (OPF) has been investigated (Holland 
et al., 2003). This system has been extended to enable the dual delivery of IGF-1 and TGF-β 
by loading the two growth factors into either the OPF hydrogel phase or the gelatin 
microparticle phase of composites. Release profiles were successfully manipulated by 
altering the phase of growth factor loading and the extent of microparticle cross linking 
(Holland et al., 2005).  
Environmentally responsive systems are able to match a patient’s physiological needs at the 
appropriate time and/or the correct site. They are able to deliver a certain amount of growth 
factor(s) in response to a biological state (Qiu & Park, 2001). They are constituted by 
sensitive hydrogels that can control the release of drugs by changing the gel structure 
according to environmental stimulation, such as temperature, pH, and/or ion concentration. 
Temperature-sensitive hydrogels are able to swell or shrink as the temperature of the 
surrounding fluid varies (Ramanan et al., 2006). The poly-N-isopropylacrylamide 
(PNIPAAm) hydrogel is a typical example of temperature-sensitive hydrogel, featuring sol-
to-gel transition at a critical solution temperature of about 35 °C. This polymer releases the 
drug with the transition from gel to sol (Zhang et al., 2004), and is of particular interest in 
those clinical situations, such as tissue ischemia, characterized by low tissue temperature. 
Similarly, pH-sensitive polymers contain pendant acidic (e.g., carboxylic and sulphonic 
acids) or basic (e.g., ammonium salts) groups that either accept or release protons in 
response to changes in environmental pH (Qiu & Park, 2001). Such polymers can release a 
drug when the environmental pH decrease. These acidic pH-sensitive polymers may be 
useful for the treatment of tissue ischemia and inflammation (Matsusaki & Akashi, 2005). A 
very recent work has also shown the capability of new magnetic particles embedded in 
polymer gels, termed ferrogels, to release drugs in response to magnetic fields (Zhao et al., 
2011). Here the authors created alginate-based porous scaffolds containing the arginine-
glycine-aspartic acid amino acid sequence, covalently coupled with the alginate and 
embedded with 10 nm iron oxide particles. Under applied magnetic fields this 
superparamagnetic gel undergoes prompt deformation, causing water flow through the 
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interconnected pores, thus triggering the release of biological agents. The authors here 
showed the capability of these ferrogels to promptly release several drugs, including 
mitoxantrone, plasmid DNA,  chemokines, as well as cells under the control of external 
magnetic fields in vitro and in vivo (Zhao et al., 2011). In our laboratory, we have been 
working on a novel and still poorly investigated strategy using polymeric 
pharmacologically active microspheres (PAM), 50-100 µm in diameter, with an in vivo half-
life of 1 month, that encapsulate bioactive factors gradually released into the injection area 
(Tatard et al., 2005; Madonna & De Caterina, 2009), and providing a vehicle for stem cell, 
drug, growth factors and gene delivery (Fig. 1). The chemical composition of these polymers 
is based on FDA-approved compounds, namely, polylactic acid (PLA), poly-D,L-lactic-co-
glycolic (PLGA), and polycaprolactone (PCL) (Mudargi et al., 2008). PAM also satisfy the 
need for resistance to accelerated degradation that may happen in the harsh 
microenvironment of tissue ischemia. In addition, compared with other polymers, PLGA 
has more hydrophilic domains, which favors cell attachment,  and therefore constitute a 
good support material for bioactive molecules that mobilize and home circulating 
progenitor/stem cells to the injured area (Tatard et al., 2005).  
 
 
Fig. 1. The concept of multifunctional pharmacologically active microspheres (PAM). 
Surface-coated PLGA microparticles form a generic platform that can be functionalized with 
drugs, growth factors or genes and externally coated with stem cells. Abbreviations: PLGA, 
poly-D,L-lactic-co-glycolic; HGF, hepatocyte growth factor; VEGF, vascular endothelial 
growth factors; MSCs, mesenchymal stem cells; CSCs, cardiac stem cells. 
5. The gene delivery approach 
Beside the incorporation into a carrier vehicle, different approaches and strategies for direct 
delivery of growth factors have been employed, including the delivery of growth factor 
genes. In order to mimic the natural healing process of the tissue successfully, this strategy 
mostly requires a localized application of multiple, rather than one, genes that encode for 
and activate the synthesis of sequential multiple growth factors with synergistic effects on 
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tissue regeneration (De Laporte et al., 2009; Donofrio et al., 2010; Fujii et al., 2011; Liu et al., 
2011). However, low transfection efficiencies, inefficient gene targeting, low gene expression 
levels, and undesired gene integration into host DNA are all challenges that may undermine 
growth factor gene delivery as a better approach instead of the growth factor protein 
delivery (Juillerat-Jeanneret & Schmitt, 2007). Gene delivery can be performed either by 
directly introducing the delivery vector into the anatomical site (in vivo) or by harvesting 
cells from the patient, transferring the gene(s) to the cells in tissue culture and then 
transferring the genetically modified cells back into the patient (ex vivo). In another recent 
review article we have specifically discussed cell-mediated HGF/Met gene transfer for 
myocardial regeneration (Madonna et al., 2010). A more general overview of preclinical 
studies using in vivo and ex vivo gene delivery strategies is provided here. 
In vivo approaches 
An in vivo gene delivery approach can be accomplished either by direct injection of viral 
vectors or transfection reagents into the site, or by attaching the delivery vector to the 
scaffold (Bleiziffer et al., 2007). This latter approach is more straightforward, but is limited 
by inefficient gene delivery and nonspecific cellular targeting. An early evaluation of in vivo 
gene delivery for therapeutic angiogenesis involved the direct intramyocardial injection of 
VEGF DNA using an adenovirus vector in patients with otherwise inoperable coronary 
artery disease and intractable angina pectoris (Rosengart et al., 1999). Phase I clinical trials 
documented the safety and feasibility, but not clear-cut clinically relevant efficacy of gene 
transfer using plasmid DNA, most likely because of the low levels of growth factor achieved 
with single injections of plasmid DNA (Rosengart et al., 1999). As of today, most clinical 
trials have failed to show any benefit of VEGF in vivo gene therapy, even by using different 
routes of intramyocardial administration that can achieve the transfer of high doses of the 
specific DNA, such as with percutaneous guidance catheter systems. The double-blind, 
placebo-controlled NOGA angiogenesis Revascularization Therapy: assessment by RadioNuclide 
Imaging (NORTHERN) study showed no benefit of plasmid DNA-VEGF gene therapy at 3 
and 6 months in terms of change in myocardial perfusion from baseline in patients with 
refractory Canadian Cardiovasculart Society (CCS) class 3 angina (Stewart et al., 2009). 
Ex vivo approaches 
Although traditional delivery of cells associated with growth factors is still a candidate 
strategy in laboratory-based trials , the most frequently investigated cell transplantation in 
tissue engineering to date is cell-based gene therapy. This therapy typically relies on 
transplanting cells, such as stem cells, lymphocytes, fibroblasts, or – alternatively – the cells 
of interest, that are removed from the body and injected after therapeutic transgene 
modifications (Fischer et al., 2009; Cho & Marban, 2010; Madonna et al., 2010). This ex vivo 
approach allows for targeting of specific cells for gene delivery, supplies cells that may 
directly participate in the regenerative process, allows for both autocrine and paracrine 
effects from the expressed growth factor, and avoids the safety risks of directly injecting 
viral vectors or transfection reagents in vivo. This approach, however, involves an extra step 
to manipulate and expand cells in tissue culture, and has the risk of contamination. 
Additionally, the ex vivo approach does not eliminate the possibility of retroviral vectors 
causing insertional activation of other genes, the over-expression of which may cause 
cancer, as experienced when using ex vivo gene therapy for the treatment of children with X-
linked severe combined immune deficiency (Gansbacher & European Society of Gene 
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Therapy, 2003). Progress in the field of gene therapy has been limited by safety concerns 
related to delivery vectors. Genetically modified cells are potentially able to provide a stable 
source of growth factors at a level that is sufficient to elicit a biological response. Autologous 
cells may also be used in this approach via the isolation of a small number of differentiated 
adult cells or stem cells, followed by in vitro expansion to produce an appropriate supply. 
The cells may naturally secrete or be genetically modified in vitro to overexpress the factor, 
either transiently or permanently. After their genetic modification, the cells are allowed to 
grow in vitro and increase in number, so as to synthesize and secrete the desired growth 
factors at the site where they have been transplanted. This approach may be particularly 
appropriate for delivery of growth factors that act by paracrine or juxtacrine mechanisms. 
6. Lentiviral and non-lentiviral vectors for gene delivery into stem cells 
The introduction of growth factor genes in stem cells can be performed by using viral or 
non-viral vectors. In the choice of using viral vectors, important experimental variables for a 
successful gene therapy include the multiplicity of infection (MOI), time length for viral 
incubation and medium used for viral incubation. An optimal combination of such 
experimental conditions would increase gene transfer efficiency and possibly obviate the 
need for selective antibiotic-based enrichment and long-term culture, which may contribute 
to senescence or compromise the long-term engraftment efficiency and/or multipotency of 
grafted cells (Rombouts & Ploemacher, 2003). In addition, by increasing gene transfer 
efficiency, fewer cells may be required to achieve a therapeutic effect. This justifies the use of 
lentiviral vectors for transducing adult stem cells, by virtue of their ability to transduce both 
dividing and non-dividing cells and their relative ease of use and comparable nature to 
adeno-associated viral (AAV) vectors, which are clinically preferred. For the transduction of 
adult stem cells, lentivirus-based systems are virtually ideal, since they overcome most 
problems, including the short duration of gene expression and the occurrence of significant 
inflammatory responses, which plague other types of gene vectors (such as adenoviruses). 
Lentiviruses are a subgroup of retroviruses that include the human type 1 
immunodeficiency virus (HIV). While retroviral systems are inefficient in transducing non-
dividing or slowly dividing cells, lentivirus-based vectors, after being pseudotyped with 
vesicular stomatitis virus glycoprotein G (VSV-G) (i.e., using the glycoprotein envelope 
from the vesicular stomatitis virus to package recombinant retroviruses) (Emi et al., 1991), 
can mediate genome integration into both non-dividing and dividing cells (Fig. 2). There is 
evidence that lentiviral vectors can also transduce more primitive, quiescent progenitors 
with stable transgene integration (Case et al., 1999). In comparison with other retroviral 
vectors, lentiviral systems allow the immediate transduction without prior expansion, or 
with growth factor stimulation for only short exposure times. Compared with adenoviral 
vectors, lentiviral vectors also offer the major advantages of causing little or no disruption of 
the target cells and of not promoting any inflammatory response (Lever, 1996). AAV vectors 
represent an alternate type of vector that may also be used for long-term transgene 
expression in the heart through cell-based therapy (Svensson et al., 1999). Like lentiviruses, 
AAV can stably integrate into the host genome providing long-term transgene expression, 
with a minimum inflammatory response. However, AAV can cause insertional mutagenesis 
and can only carry genes which are less than 5 kb (Donsante et al., 2007). A possible 
drawback of the use of lentiviral and AAV vectors for delivering genes that encode for 
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growth factors might be that they can cause a chronic overexpression of the protein, with 
an uncertain therapeutic effect. Short-term gene expression of the growth factor gene 
would be desirable if the goal is to deliver a secreted protein, such as insulin-like growth 
factor-1 (IGF-1), vascular endothelial growth factor (VEGF) and HGF, while long-term 
expression would be preferable if the goal is to express membrane proteins such as 
receptors for growth factors that require stable expression. Possible strategies to induce 
short-term gene expression of the transgene include plasmid transfection or the use of 
adenoviral vectors (Rabbany et al., 2009). Limitations of these strategies are the low 
transfection efficiency with plasmids and the immunogenic response of the host with 
adenoviruses.  
 
 
Fig. 2. Schematic representation of the transducing vector construct (a), packaging construct 
(b, c) and VSV-G Env-expressing construct (d). Abbreviations: Amp: ampicillin resistance 
gene; ΔU3: deleted region of the 3’LTR, which allows for biosafety of the vector; Gag, pol, 
env: genes codifying for envelope proteins; PCMV: cytomegalovirus promoter; 3’-LTR: 3’-
long terminal repeats for viral packaging; PRSV: Rous Sarcoma Virus (RSV) enhancer/ 
promoter; 5’-LTR: 5’-long terminal repeats for viral packaging; w psi: packaging sequence 
for viral packaging; pA: polyadenylation signal; RRE: HIV-1 Rev response element; VSV-G: 
G glycoprotein gene from Vesicular Stomatitis Virus (VSV-G) as a pseudotyping envelope. 
(e) Photographs representing the experimental steps of production of the lentiviral stock 
(containing the packaged expression construct) by cotransfecting the packaging construct (b, 
c), the VSV-G Env-expressing construct (d) and transducing vector construct (a) into the 
293FT virus-producing cell line. The expression of the VSV-G glycoprotein causes 293FT 
cells to fuse, resulting in the appearance of large, multinucleated cells known as syncytia. 
7. Conclusions  
Growth factor delivery and tissue engineering have emerged as new concepts that focus 
on tissue regeneration from cells with the support of biomaterials and growth factors 
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(Ikada, 2006). Various delivery methods are available to administer growth factors to 
ischemic tissues. Among these strategies, the cell-based delivery of growth factor genes is 
of great potential interest, since the in situ expression of the growth factor gene may result 
in higher and more constant levels of protein production. With respect to the delivery of 
growth factors, a major challenge is to identify growth factors and signaling pathways 
that selectively promote proliferation, migration, engraftment and differentiation of 
resident CSCs or exogenous multipotent stem cells. Current knowledge suggests that 
‘‘cocktails’’ of biomolecules (growth factors or DNA), or even more cocktails of exogenous 
stem/committed progenitor cells (myogenic or angiogenic cells) with a wide spectrum of 
differentiation capabilities, should be delivered locally, in order to mimic, as far as 
possible, the different requirements of the ischemic tissue during the different 
regeneration phases. To deliver multiple growth factor genes and stem cells with distinct 
release and dynamic profiles, a greater understanding of the requirements for 
regenerating complex and functional tissues such as the myocardium is necessary. 
Challenges in this area revolve on controlling reciprocal interactions among those cells 
and signals. Winning these challenges would open a new era in stem cell and gene 
therapy research for both laboratory-based scientists and practicing physicians. From a 
bedside point of view, preclinical studies in large animals (such as porcine model) are 
required to carefully evaluate potential human therapies.  
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